Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
Multi-center, Single Blind, Randomized, Parallel Study to Compare the Clinical Efficacy and Safety of Dusama (Budesonide) HFA MDI With Pulmicort (Budesonide) Turbuhaler in Mild to Moderate Chinese Asthma Patients
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Tianjin, China, 300393
- Tianjin First Central Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100044
- Peking University People's Hospital
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510650
- The First Affiliated Hospital of Jinan University
-
Meizhou, Guangdong, China, 514031
- Meizhou People's Hospital
-
-
He Bei Sheng
-
Shijia Zhuang, He Bei Sheng, China, 050017
- The Second Hospital of Hebei Medical University
-
-
Heilongjiang
-
Daqing, Heilongjiang, China, 163411
- Daqing Oil Field Hospital
-
-
Inner Mongolia
-
Baotou, Inner Mongolia, China, 014000
- Bao Gang Hospital
-
Hohhot, Inner Mongolia, China, 010100
- The Affiliated Hospital of Inner Mongolia Medical University
-
-
Jilin
-
Tonghua, Jilin, China
- Meiheko Central Hospital
-
-
Shan XI Sheng
-
Taiyuan, Shan XI Sheng, China, 030001
- The First Affiliated Hospital of Shanxi Medical University
-
Taiyuan, Shan XI Sheng, China, 030012
- Shanxi Provincial People's Hospital
-
-
Shandon
-
Jining, Shandon, China, 272000
- Affiliated Hospital of Jining Medical University
-
Qingdao, Shandon, China, 266011
- Qingdao Municipal Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 to 70 years old and diagnosed as Asthma in clinics
- Diagnosed as Asthma according to the 2016 Asthma guidance of Chinese Thoracic Society, and without administer corticosteroids within three months, either new or old patients
- FEV1 predicted ≧ 60%
- Patients is willing to participate the study and signed the Informed Consent Form
Exclusion Criteria:
- Allergy to budesonide or salbutamol
- Infections of Respiratory tract, nasal-sinus and ear within 4 weeks before enrollment
- Severe nasal allergy and need the treatment of corticostreoids and histamines.
- Severe cardiovascular disease history
- Has used leukotriene receptor antagonist (Montelukast, Pranlukast, Zafirlukast etc.) within 2 weeks before enrollment
- Severe cognition or mental disorder and can not cooperation with the treatment
- Significant liver dysfunction, AST, ALT > 3 X normal upper limits, CR > 1.5 X normal upper limits
- Patients with uncontrolled diabetes or fasting blood glucose > 10 mmol/L
- Patients currently receiving beta-antagonists or beta-agonists treatment (including eye drops)
- Patients who has contraindications to beta2-agonists
- Patients who has participated others drug's clinical study within three months
- Female patients who are pregnant or lactation or prepare to pregnant
- Any conditions which the investigators considered not suitable to enrolled
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Budesonide HFA MDI (Treatment A)
Participants assigned to Experimental arm will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks
|
Participants will inhaled 2 puffs of budesonide 200 mcg HFA MDI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
Other Names:
|
|
Active Comparator: Budesonide DPI (Turbuhaler) (Treatment B)
Participants assigned to Active Comparator arm will inhaled 4 puffs of budesonide 100 mcg powder for inhalation bid (am 08:00 and pm 16:00) for 4 weeks
|
Participants will inhaled 4 puffs of budesonide 100 mcg DPI bid (am 08:00 and pm 16:00) for 4 weeks, if necessary rescue Ventolin (Salbutamol Sulfate) 100 mcg 2 puffs could be used with maximum daily dose of 8 puffs.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from base line of FEV1
Time Frame: Week 0, 2 and 4
|
The change from base line of forced expiratory volume in one second after 4 weeks treatment
|
Week 0, 2 and 4
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean change from base line of morning and evening PEF
Time Frame: Week 0 and 4
|
The mean change from base line of morning and evening PEF (peak expiratory flow)
|
Week 0 and 4
|
|
Change from base line of FVC
Time Frame: Week 0 and 4
|
The changes from base line of FVC after 4 weeks treatment
|
Week 0 and 4
|
|
Change from base line of FEV1/FVC ratio
Time Frame: Week 0 and 4
|
The changes from base line of FEV1/FVC ratio after 4 weeks treatment
|
Week 0 and 4
|
|
Change from base line of FEF25%
Time Frame: Week 0 and 4
|
The changes from base line of FEF25% after 4 weeks treatment
|
Week 0 and 4
|
|
Change from base line of FEF50%
Time Frame: Week 0 and 4
|
The changes from base line of FEF50% after 4 weeks treatment
|
Week 0 and 4
|
|
Change from base line of FEF75%
Time Frame: Week 0 and 4
|
The changes from base line of FEF75% after 4 weeks treatment
|
Week 0 and 4
|
|
Change from base line of ACT
Time Frame: Week 0, 2 and 4
|
The change from base line of Asthma Control Test after 4 weeks treatment
|
Week 0, 2 and 4
|
|
Daily PEF variability
Time Frame: during week 0 to 4
|
The Daily PEF variability (= (daily highest PEF-daily lowest PEF)X2/((daily highest PEF+daily lowest PEF) X 100% during the whole treatment period
|
during week 0 to 4
|
|
Weekly PEF variability
Time Frame: during week 0 to 4
|
The Weekly PEF variability (= (biweely highest PEF-biweekly lowest PEF)X2/((biweekly highest PEF+biweekly lowest PEF) X 100% during the whole treatment period
|
during week 0 to 4
|
|
Changes of day time and night time symptom
Time Frame: during week 0 to 4
|
The changes of day time and night time symptom during the treatment period
|
during week 0 to 4
|
|
Subjects number with acute exacerbation
Time Frame: during week 0 to 4
|
The total number of subjects with acute exacerbation during treatment period
|
during week 0 to 4
|
|
Total amount of rescue medication, Ventolin 100 mcg inhaler, used
Time Frame: during week 0 to 4
|
The total amount of doses of rescue medication, Ventolin 100 mcg inhaler, used during the treatment period
|
during week 0 to 4
|
|
Percentage of days without symptom
Time Frame: during week 0 to 4
|
The percentage of days without asthma symptom during the treatment period
|
during week 0 to 4
|
|
Percentage of days without using rescue medicine
Time Frame: during week 0 to 4
|
The percentage of days without using rescue medicine during the treatment period
|
during week 0 to 4
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Wei Hsiu Wu, MBA, Intech Biopharm
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Immune System Diseases
- Lung Diseases
- Hypersensitivity, Immediate
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Budesonide
Other Study ID Numbers
Other Study ID Numbers
- INTB011H01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.